Hikma Pharmaceuticals's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was $1.05.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $2.26.
During the past 12 months, Hikma Pharmaceuticals's average earnings per share (NRI) Growth Rate was -3.40% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 4.50% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 5.30% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 7.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Hikma Pharmaceuticals's EPS without NRI or its related term are showing as below:
HKMPF'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -6.5 Med: 10.9 Max: 59.4
Current: 4.5
During the past 13 years, Hikma Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 59.40% per year. The lowest was -6.50% per year. And the median was 10.90% per year.
HKMPF's 3-Year EPS without NRI Growth Rate is ranked worse than 57.89% of 786
companies
in the Drug Manufacturers industry
Industry Median: 9.6
vs HKMPF: 4.50
Hikma Pharmaceuticals (OTCPK:HKMPF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Hikma Pharmaceuticals EPS without NRI Related Terms
Hikma Pharmaceuticals EPS without NRI Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKMPF vs ZTS, UTHR, VTRS: EPS without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPF) has a EPS without NRI of $2.26 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Hikma Pharmaceuticals and its competitors. According to the industry distribution chart, Hikma Pharmaceuticals ranks #455 out of 786 companies in the Drug Manufacturers industry, placing it in the top 57.9%.
Is Hikma Pharmaceuticals' EPS without NRI too high?
Hikma Pharmaceuticals' current EPS without NRI is $2.26. The Drug Manufacturers industry median EPS without NRI is 9.60. Hikma Pharmaceuticals' value of $2.26 is 76.5% below this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #455 out of 786 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #455 out of 786 companies for EPS without NRI. This places Hikma Pharmaceuticals in the lower half of its industry. The industry median EPS without NRI is 9.60. Hikma Pharmaceuticals' value of $2.26 is 76.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current EPS without NRI of $2.26 is 76.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current EPS without NRI is $2.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.51, compared to a current price of $20.12 — trading 29.4% below its estimated fair value. The current EPS without NRI is $2.26 and 76.5% below the Drug Manufacturers industry median of 9.60. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current EPS without NRI is $2.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.12 is trading 29.4% below its estimated GF Value™ of $28.51.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
EPS without NRI: $2.26
GF Value™: $28.51 vs. price of $20.12 (29.4% below fair value)
Industry Position: 76.5% below the Drug Manufacturers median (#455 of 786)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
